

Paul Rolf Jensen CSB #154013  
**JENSEN & ASSOCIATES**  
*Trial Lawyers*  
 650 Town Center Drive, 12<sup>th</sup> Floor  
 Costa Mesa, CA 92626  
 (714) 662-5527

Attorneys for Plaintiff LUIS SANDOVAL  
 and THE PROPOSED CLASS

**UNITED STATES DISTRICT COURT**  
**CENTRAL DISTRICT OF CALIFORNIA – WESTERN DIVISION**

LUIS SANDOVAL, on behalf of himself  
 and all others similarly situated,

Plaintiff,

v.

HERITAGE PHARMACEUTICALS,  
 INC., a Delaware corporation; HERITAGE  
 PHARMACEUTICALS, INC. d/b/a AVET  
 PHARMACEUTICALS, INC.; and DOES  
 1 to 50, inclusive,

Defendants.

)Case No.:

)

)CLASS ACTION COMPLAINT FOR:

)

**1. BREACH OF THE IMPLIED  
 WARRANTY OF  
 MERCHANTABILITY**

)

**2. UNJUST ENRICHMENT**

)

**3. FRAUDULENT CONCEALMENT**

)

**4. FRAUD**

)

**5. CONVERSION**

)

**6. VIOLATION OF CALIFORNIA  
 UNFAIR COMPETITION LAW**

)

**[CAL. BUS. & PROF. CODE §17200, et  
 seq.]**

)

)DEMAND FOR JURY TRIAL

)

)

)

Plaintiff Luis Sandoval (“Plaintiff”) brings this action on behalf of himself and all others  
 similarly situated against Defendant Heritage Pharamaceuticals, Inc. d/b/a Avet Pharmaceuticals  
 Inc. (“Avet” or “Defendant”). Plaintiff makes the following allegations pursuant to the  
 investigation of his counsel and based upon information and belief, except as to allegations  
 specifically pertaining to himself, which are based on personal knowledge.

**CLASS ACTION COMPLAINT**

**JURISDICTION**

1. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §1332(d)(2)(A), as modified by the Class Action Fairness Act of 2005, because:

- a. The Proposed Class includes over 100 members, and the named plaintiff and class members are citizens states that are diverse from the state of Defendants' citizenship, the amount in controversy in this class action exceeds five million dollars (\$5,000,000), exclusive of interest and costs; and
- b. Defendants have purposefully availed themselves of the privilege of conducting business activities within the State of California by regularly conducting business within this judicial district at all time relevant hereto.

**VENUE**

2. Venue is proper in this judicial district pursuant to 28 U.S.C. §1391, because a substantial part of the acts or omissions complained of herein occurred in this judicial district, and Defendants caused harm to the named Plaintiff and numerous class members in this judicial district.

**PARTIES**

3. Plaintiff Luis Sandoval is a citizen of California who resides in the City of Bellflower, in the County of Los Angeles. Mr. Sandoval has been taking metformin since at least 2010. At all times relevant herein, Mr. Sandoval was prescribed, purchased, and consumed metformin manufactured by Defendant, for which he paid a co-pay of \$35.00. Upon learning of the metformin defect, Mr. Sandoval discovered that he had been taking the

1 defective metformin manufactured by Avet. When purchasing metformin from  
2 Defendant, Mr. Sandoval reviewed the accompanying labels and disclosures, and  
3 reasonably understood them to be representations and warranties by the manufacturer,  
4 distributor, and pharmacy that the medication was properly manufactured, free from  
5 defects, and safe for its intended use. Mr. Sandoval relied on these representations and  
6 warranties in deciding to purchase Defendant's metformin, and these representations and  
7 warranties were part of the basis of the bargain, in that he would not have purchased  
8 metformin from Defendant if he had known it was not, in fact, properly manufactured  
9 and free from defects. Mr. Sandoval further understood that each purchase involved a  
10 direct transaction between himself and Avet because his medication came with packaging  
11 and other materials prepared by Avet, including representations and warranties that his  
12 medication was properly manufactured and free from defects.

- 13  
14  
15  
16 4. Defendant Heritage Pharmaceuticals, Inc. d/b/a Avet Pharmaceuticals Inc. is a Delaware  
17 corporation with a principal place of business at One Tower Center Boulevard, East  
18 Brunswick, New Jersey 08816. Avet conducts substantial business throughout the United  
19 States, and specifically in the State of California. Avet has been engaged in the  
20 manufacturing, distribution, and sale of defective metformin in the United States,  
21 including in the State of California.  
22

23  
24 **COMMON ALLEGATIONS**

- 25 5. This is a class action lawsuit regarding Defendant's manufacturing, distribution, and sale  
26 of the generic medication metformin that contains dangerously high levels of N-  
27 nitrosodimethylamine ("NDMA"), a carcinogenic and liver-damaging impurity.  
28

- 1 6. Metformin is a prescription medication that has been sold under brand names such as  
2 Glucophage. Metformin is primarily used to control high blood sugar in patients with  
3 Type 2 diabetes. However, Avet's manufacturing process has caused their metformin to  
4 contain dangerously high levels of NDMA.  
5
- 6 7. NDMA is a semivolatile organic chemical. According to the United States Environmental  
7 Protection Agency ("EPA"), NDMA "is a member of the N-ni-trosamines, a family of  
8 potent carcinogens." While NDMA is not currently produced in the United States other  
9 than for research purposes, it was formerly used "in production of liquid rocket fuel,"  
10 among other uses. NDMA is listed a "priority toxic pollutant" in federal regulations. 40  
11 C.F.R. §131.36. Exposure to NDMA can cause liver damage and cancer in humans.  
12 NDMA is classified as a probable human carcinogen and animal studies have shown that  
13 "exposure to NDMA has caused tumors primarily of the liver, respiratory tract, kidney  
14 and blood vessels."  
15
- 16 8. On March 2, 202, Valisure, an online pharmacy registered with the United States Drug  
17 Enforcement Agency ("USDEA") and Food & Drug Administration ("FDA"), "detected  
18 high levels of N-Nitrodimethylamine ('NDMA') in specific batches of prescription drug  
19 products containing metformin."<sup>1</sup> This included metformin manufactured by Avet.<sup>2</sup>  
20  
21 9. Avet had not yet issued a recall of its defective metformin and continues to represent on  
22 its website that it manufactures "high quality generic medicines." However, these  
23 representations are false, as Defendant's metformin medication contains the carcinogenic  
24 impurity NDMA.  
25

## 26 I. METFORMIN IS MARKETING AS SAFE 27 28

---

<sup>1</sup> VALISURE, VALISURE CITIZEN PETITION ON METFORMIN (2020), (Exhibit 1).

<sup>2</sup> *Id.* at 10.

1 10. Avet has always marketed metformin as a safe and effective product and has continued to  
2 do so despite the findings of Valisure

3 11. Metformin is one of the most prescribed and successful drugs in history. In 2017, over  
4 78.6 million prescriptions written for the drug in the United States alone.<sup>3</sup>

5 12. On Avet's website, the company states that it manufactures "high quality generic  
6 medicines."

7  
8 **II. DEFENDANT'S METFORMIN CONTAINS DANGEROUS LEVELS OF NDMA**

9 13. Contrary to the above assertions, Avet's metformin contains dangerously high levels of  
10 NDMA that would not be present if the medication were properly and safely  
11 manufactured. As noted above, Valisure has found unacceptable levels of NDMA in  
12 samples of metformin manufactured by Avet.

13 14. While the cause of the NDMA contamination in metformin is still being investigated,  
14 Valisure notes that "the presence of NDMA in metformin products may be primarily due  
15 to contamination during manufacturing as opposed to a fundamental instability of the  
16 drug molecule."<sup>4</sup>

17 15. The FDA has "set strict daily acceptable intake limits on NDMA in pharmaceuticals of  
18 96 nanograms."<sup>5</sup> But Valisure found that Avet's metformin has an NDMA content that is  
19 between 5.3 to nearly 9 times the daily intake limit.<sup>6</sup>

20 16. The presence of NDMA in metformin is particularly troubling because, by its very  
21 nature, it is intended to be taken daily.  
22

23  
24  
25  
26  
27 <sup>3</sup> Number of metformin hydrochloride prescriptions in the U.S. from 2004 to  
28 2017, STATISTA, <https://www.statista.com/statistics/780332/metformin-hydrochloride-prescriptions-number-in-the-us/> (last accessed June 17, 2020).

<sup>4</sup> VALISURE PETITION at 3.

<sup>5</sup> *Id.* at 1.

<sup>6</sup> *Id.* at 10.

1 17. Pursuant to its findings, Valisure recommended that Avet recall its metformin  
2 medications.

3 **III. PLAINTIFF WAS HARMED BY PURCHASING AND CONSUMING**  
4 **DEFENDANT'S DEFECTIVE METFORMIN**  
5

6 18. Plaintiff and the Proposed Class were injured by paying the full purchase price of their  
7 metformin medications. These medications are worthless, as they contain harmful levels  
8 of NDMA. As the medications expose users to NDMA levels well above the legal limit,  
9 the medications are not fit for human consumption. Plaintiff is further entitled to statutory  
10 damages, damages for the injury sustained in consuming high levels of acutely-toxic  
11 NDMA, and for damages related to Defendant's conduct.  
12

13 19. Plaintiff brings this action on behalf of himself and the Proposed Class for equitable relief  
14 and to recover damages and restitution for: (i) breach of the implied warranty of  
15 merchantability; (ii) unjust enrichment; (iii) fraudulent concealment; (iv) fraud; (v)  
16 conversion; and (vi) violation of California's Unfair Competition Law, Business and  
17 Professions Code §17200, *et seq.*  
18  
19  
20

21 **CLASS ALLEGATIONS**

22 20. Plaintiff seeks to represent a class defined as all persons in the California who purchased  
23 metformin manufactured by Avet (the "Proposed Class"). Specifically excluded from the  
24 Class are persons who made such purchase for the purpose of resale, Defendant,  
25 Defendant's officers, directors, agents, trustees, parents, children, corporations, trusts,  
26 representatives, employees, principals, servants, partners, joint ventures, or entities  
27 controlled by Defendant, and their heirs, successors, assigns, or other persons or entities  
28

1 related to or affiliated with Defendant and/or Defendant's officers and/or directors, the  
2 judge assigned to this action, and any member of the judge's immediate family.

3  
4 21. Subject to additional information obtained through further investigation and discovery,  
5 the foregoing definition of the Proposed Class may be expanded or narrowed by  
6 amendment or amended complaint.

7 22. **Numerosity.** The members of the Proposed Class are geographically dispersed  
8 throughout the State of California and are so numerous that individual joinder is  
9 impracticable. Upon information and belief, Plaintiff reasonably estimates that there are  
10 hundreds of thousands of members in the Proposed Class. Although the precise number  
11 of Proposed Class members is unknown to Plaintiff, the true number of Proposed Class  
12 members is known to Defendant and may determined through discovery. Proposed Class  
13 members may be notified of the pendency of this action by mail and/or publication  
14 through the distribution records of Defendant and third-party retailers and vendors.  
15

16  
17 23. **Common Questions of Law and Fact Predominate.** Common questions of law and fact  
18 exist as to all members of the Proposed Class and predominate over any questions  
19 affecting only individual Proposed Class members. These common legal and factual  
20 questions include, but are not limited to, the following:  
21

- 22 a. Whether the metformin manufactured by Defendant contains dangerously high  
23 levels of NDMA, thereby breaching the implied warranties made by Defendant  
24 and making the metformin unfit for human consumption and therefore unfit for its  
25 intended purpose.  
26  
27  
28



- b. Whether Defendant know or should have known that metformin contained elevated levels of NDMA prior to selling the medication, thereby constituting fraud and/or fraudulent concealment;
- c. Whether Defendant has unlawfully converted money from Plaintiff and the Proposed Class;
- d. Whether Defendant is liable to Plaintiff and the Proposed Class for unjust enrichment;
- e. Whether Defendant is liable to Plaintiff and the Proposed Class for fraudulent concealment;
- f. Whether Plaintiff and the Proposed Class have sustained monetary loss and the proper measure of that loss;
- g. Whether Plaintiff and the Proposed Class are entitled to declaratory and injunctive relief;
- h. Whether Plaintiff and the Proposed Class are entitled to restitution and disgorgement from Defendant; and
- i. Whether the marketing, advertising, packaging, labeling, and other promotional materials for metformin are deceptive.

24. **Typicality.** Plaintiff's claims are typical of the claims of the other members of the Proposed Class in that Defendant mass marketed and sold defective metformin to consumers throughout California. All of the metformin manufactured by Defendant contained this defect. Therefore, Defendant breached its implied warranties to Plaintiff and the Proposed Class by manufacturing, distributing, and selling the defective metformin. Plaintiff's claims are typical in that he was uniformly harmed in purchasing



1 and consuming the defective metformin. Plaintiff's claims are further typical in that  
2 Defendant deceived Plaintiff in the very same manner as they deceived each member of  
3 the Proposed Class. Further, there are no defenses available to Defendant that are unique  
4 to Plaintiff.  
5

6 **25. Adequacy of Representation.** Plaintiff will fairly and adequately protect the interests of  
7 the Proposed Class. Plaintiff has retained counsel that is highly experienced in complex  
8 Plaintiff-side litigation, and Plaintiff intends to vigorously prosecute this action on behalf  
9 of the Proposed Class. Furthermore, Plaintiff has no interest that are antagonistic to those  
10 members of the Proposed Class.  
11

12 **26. Superiority.** A class action is superior to all other available means for the fair and  
13 efficient adjudication of this controversy. The damages or other financial detriment  
14 suffered by individual Proposed Class members are relatively small compared to the  
15 burden and expense of individual litigation of their claims against Defendant. It would  
16 thus be virtually impossible for the Proposed Class, on an individual basis, to obtain  
17 effective redress for the wrongs committed against them. Moreover, even if Proposed  
18 Class members could afford such individualized litigation, the court system could not.  
19 Individualized litigation would create the danger of inconsistent or contradictory  
20 judgments arising from the same set of facts. Individualized litigation would also increase  
21 the delay and expense to all parties and the court system from the issues raised by this  
22 action. By contrast, the class action device provides the benefits of adjudication of these  
23 issues in a single proceeding, economies of scale, and comprehensive supervision by a  
24 single court, and presents no unusual management difficulties under the circumstances.  
25  
26  
27

28 **27.** In the alternative, the Proposed Class may also be certified because:

- 1 a. The prosecution of separate actions by individual Proposed Class members would  
2 create a risk of inconsistent or varying adjudications with respect to individual  
3 Proposed Class members that would establish incompatible standards of conduct  
4 for the Defendant;  
5  
6 b. The prosecution of separate actions by individual Proposed Class members would  
7 create a risk of adjudications with respect to them that would, as a practical  
8 matter, be dispositive of the interest of other Proposed Class members not parties  
9 to the adjudications, or substantially impair or impede their ability to protect their  
10 interests; and/or  
11  
12 c. Defendant has acted or refused to act on the grounds generally applicable to the  
13 Proposed Class as a whole, thereby making appropriate final declaratory and/or  
14 injunctive relief with respect to the members of the Proposed Class as a whole.  
15

16  
17 **FIRST CAUSE OF ACTION**

18 **BREACH OF THE IMPLIED WARRANTY OF MERCHANTABILITY**  
19 **(On Behalf of The Proposed Class, Against All Defendants and Each of Them)**

- 20 28. Plaintiff repeats and reincorporates all of the allegations and averments set forth in  
21 paragraphs 1 through 25, *supra*, as if set forth in full at this point.  
22  
23 29. Plaintiff brings this claim individually on behalf of himself and on behalf of the members  
24 of the Proposed Class against Defendant.  
25  
26 30. Defendant, as the designer, manufacturer, marketer, distributor, and/or seller, impliedly  
27 warranted that metformin (i) would not contain elevated levels of NDMA and (ii) is  
28 generally recognized as safe for human consumption.

1 31. Defendant breached the warranty implied in the contract for the sale of the defective  
2 metformin because it could not pass without objection in the trade under the contract  
3 description, the metformin was not of fair or average quality within the description, and  
4 the metformin was unfit for its intended and ordinary purpose because it was defective in  
5 that it contained elevated levels of carcinogenic and liver toxic NDMA, and as such is not  
6 generally recognized as safe for human consumption. As a result, Plaintiff and the  
7 Proposed Class members did not receive the goods as impliedly warranted by Defendant  
8 to be merchantable.  
9

10  
11 32. Plaintiff and the Proposed Class members purchased metformin in reliance upon  
12 Defendant's skill and judgment and the implied warranties of fitness for a particular  
13 purpose.  
14

15 33. The metformin was not altered by Plaintiff or the Proposed Class members.

16 34. The metformin was defective when it left the exclusive control of Defendants.

17 35. Defendant knew that the metformin would be purchased and used without additional  
18 testing by Plaintiff and the Proposed Class members.

19 36. The defective metformin was defectively manufactured and is unfit for its intended  
20 purpose, and Plaintiff and the Proposed Class members did not receive the goods as  
21 warranted.  
22

23 37. As a direct and proximate result of Defendant's breach of the implied warranty of  
24 merchantability, Plaintiff and the Proposed Class members have been injured and harmed  
25 in the following ways: (a) they would not have purchased Defendant's metformin on the  
26 same terms if they knew that said metformin contained harmful levels of NDMA, and is  
27  
28

1 not generally recognized as safe for human consumption; and (b) Defendant's metformin  
2 does not have the characteristics, ingredients, uses, or benefits as promised by Defendant.  
3

4  
5 **SECOND CAUSE OF ACTION**  
6 **UNJUST ENRICHMENT**

(On Behalf of The Proposed Class, Against All Defendants and Each of Them)

7 38. Plaintiff repeats and reincorporates all of the allegations and averments set forth in  
8 paragraphs 1 through 25, *supra*, as if set forth in full at this point.

9 39. Plaintiff brings this claim individually and on behalf of the members of the Proposed  
10 Class against Defendant.  
11

12 40. Plaintiff and the Proposed Class conferred a benefit on Defendant in the form of monies  
13 paid to purchase Defendant's defective metformin.

14 41. Defendant voluntarily accepted and retained this benefit.

15 42. Because the benefit was obtained unlawfully by way of selling and accepting  
16 compensation for medications unfit for human use, it would be unjust and inequitable for  
17 Defendant to retain it without paying the value thereof.  
18

19  
20 **THIRD CAUSE OF ACTION**  
21 **FRAUDULENT CONCEALMENT**

(On Behalf of The Proposed Class, Against All Defendants and Each of Them)

22 43. Plaintiff repeats and reincorporates all of the allegations and averments set forth in  
23 paragraphs 1 through 25, *supra*, as if set forth in full at this point.  
24

25 44. Plaintiff brings this claim individually and on behalf of the members of the Proposed  
26 Class against Defendant.  
27

28 45. Defendant owed a duty to Plaintiff and the Proposed Class to disclose material facts  
given their relationship as contracting parties and intended users of metformin. Defendant

1 had a further duty to disclose material facts to Plaintiff and the Proposed Class that they  
2 were in fact manufacturing, distributing, and selling harmful metformin unfit for human  
3 consumption because Defendant had superior knowledge such that engaging in a  
4 transaction for purchase and sale of the defective metformin with Plaintiff and the  
5 Proposed Class without disclosure was inherently unfair.  
6

7 46. Defendant had knowledge of these material facts. Beginning in December 2019,  
8 Defendant was aware that NDMA was detected in metformin-containing medications in  
9 other countries.<sup>7</sup> During this time, Plaintiff and the Proposed Class members were using  
10 their medications without knowing they contained dangerous levels of NDMA.  
11

12 47. Defendant breached their duty to disclose these material facts.

13 48. In failing to disclose these material facts to Plaintiff and the Proposed Class, Defendant  
14 intended to hide from Plaintiff and the Proposed Class that they were purchasing and  
15 consuming metformin containing a harmful defect that was unfit for human use, and thus  
16 acted with scienter and/or the intent to defraud.  
17

18 49. Plaintiff and the Proposed Class reasonably relied on Defendant's failure to disclose  
19 insofar as they would not have purchased the defective metformin manufactured and sold  
20 by Defendant had they known in contained unsafe levels of NDMA.  
21

22 50. As a direct and proximate result of Defendant's breach, Plaintiff and the Proposed Class  
23 suffered damages in the amount of monies paid for the defective metformin.

24 51. Defendant's conduct was and is malicious, oppressive, and fraudulent, and in conscious  
25 disregard of Plaintiff's and the Proposed Class' rights. Defendant acted with a malicious  
26

---

27 <sup>7</sup> Statement from Janet Woodcock, M.D., director of FDA's Center for Drug  
28 Evaluation and Research, on impurities found in diabetes drugs outside the  
U.S., <https://www.fda.gov/news-events/press-announcements/statement-janet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found> (last accessed June 17, 2020).

1 state of mind arising from avarice and greed, and a willingness to vex, annoy and injure  
2 Plaintiff and the Proposed Class in order to fraudulently induce them into purchasing the  
3 defective metformin. This conduct is sufficiently oppressive, fraudulent, and despicable  
4 behavior so as to entitle Plaintiff and the Proposed Class to punitive and exemplary  
5 damages to set an example and to punish Defendant.  
6

7  
8 **FOURTH CAUSE OF ACTION**

9 **FRAUD**

10 (On Behalf of The Proposed Class, Against All Defendants and Each of Them)

11 52. Plaintiff repeats and reincorporates all of the allegations and averments set forth in  
12 paragraphs 1 through 25, *supra*, as if set forth in full at this point.

13 53. Plaintiff brings this claim individually and on behalf of the members of the Proposed  
14 Class against Defendant.

15 54. As set forth herein, Defendant provided Plaintiff and the Proposed Class members with  
16 materially false or misleading information about the metformin Defendant manufactured.  
17 Specifically, Defendant marketed metformin as safe for human consumption. As  
18 indicated above, however, these representations were and are false and misleading, as  
19 Defendant's metformin medications contain elevated levels of NDMA.  
20

21 55. The misrepresentations and omissions of material fact made by Defendant, upon which  
22 Plaintiff and the Proposed Class members reasonably and justifiably relied, were intended  
23 to induce and actually induced Plaintiff and the Proposed Class members to purchase  
24 defective metformin.  
25

26 56. Defendant knew or should have known that its metformin was contaminated with this  
27 harmful defect, but nonetheless continued to manufacture and sell it. Beginning in  
28

1 December 2019, Defendant was aware that NDMA was detected in metformin-containing  
2 medications in other countries. During this time, Plaintiff and the Proposed Class  
3 members were using their medications without knowing they contained dangerous levels  
4 of NDMA.  
5

6 57. The fraudulent actions of Defendant caused damage to Plaintiff and the Proposed Class  
7 members, who are entitled to damages and other legal and equitable relief as a result.

8 58. Defendant's conduct was and is malicious, oppressive, and fraudulent, and in conscious  
9 disregard of Plaintiff's and the Proposed Class' rights. Defendant acted with a malicious  
10 state of mind arising from avarice and greed, and a willingness to vex, annoy and injure  
11 Plaintiff and the Proposed Class in order to fraudulently induce them into purchasing the  
12 defective metformin. This conduct is sufficiently oppressive, fraudulent, and despicable  
13 behavior so as to entitle Plaintiff and the Proposed Class to punitive and exemplary  
14 damages to set an example and to punish Defendant.  
15  
16  
17

18 **FIFTH CAUSE OF ACTION**  
19 **CONVERSION**

20 (On Behalf of The Proposed Class, Against All Defendants and Each of Them)

21 59. Plaintiff repeats and reincorporates all of the allegations and averments set forth in  
22 paragraphs 1 through 25, *supra*, as if set forth in full at this point.

23 60. Plaintiff brings this claim individually and on behalf of the members of the Proposed  
24 Class against Defendant.

25 61. Plaintiff and the Proposed Class have an ownership right to the monies paid for the  
26 defective metformin manufactured by Defendant.  
27  
28



1 62. Defendant has wrongfully asserted dominion over the payments illegally obtained by  
2 them in exchange for the defective metformin. Defendant has done so every time that  
3 Plaintiff and the Proposed Class purchased their metformin.  
4

5 63. As a direct and proximate result of Defendant's wrongful assertion of dominion over the  
6 sums of money paid by Plaintiff and the Proposed Class for Defendant's metformin,  
7 Plaintiff and the Proposed Class have suffered damages in the total amount of payments  
8 made each time they bought Defendant's metformin.  
9

10  
11 **SIXTH CAUSE OF ACTION**

12 VIOLATION OF CALIFORNIA UNFAIR COMPETITION LAW [CAL. BUS. & PROF.  
13 CODE §17200, *et seq.*]

(On Behalf of The Proposed Class, Against all Defendants and Each of Them)

14 64. Plaintiff repeats and reincorporates all of the allegations and averments set forth in  
15 paragraphs 1 through 25, *supra*, as if set forth in full at this point.

16 65. Plaintiff brings this claim individually and on behalf of the members of the Proposed  
17 Class against Defendant.  
18

19 66. By committing the acts and practices alleged herein, Defendant violated California's  
20 Unfair Competition Law ("UCL"), CAL. BUS. & PROF. CODE §17200, *et seq.* as to the  
21 Proposed Subclass, by engaging in unlawful, fraudulent, and unfair conduct.  
22

23 67. Defendant violated the UCL's proscription against engaging in unlawful conduct as a  
24 result of its violations of the CLRA, California Civil Code §§1770(a)(5), (a)(7), (a)(9),  
25 and (a)(16).  
26

27 68. Defendant's acts and practices described herein violate the UCL's prescription against  
28 engaging in fraudulent conduct.

1 69. As discussed in greater detail above, specifically, Defendant marketed metformin as safe  
2 for human consumption. However, these representations were and are false and  
3 misleading as Defendant's metformin medications contained elevated levels of NDMA.  
4 These representations were likely to deceive reasonable consumers.  
5

6 70. Defendant's acts and practices described above also violate the UCL's proscription  
7 against engaging in unfair conduct.  
8

9 71. Plaintiff and members of the Proposed Class suffered a substantial injury by virtue of  
10 buying metformin that they would not have purchased absent Defendant's unlawful,  
11 fraudulent, and unfair marketing, advertising, packaging, and omission about the  
12 contaminated nature of its metformin medication, or by virtue of paying an excessive  
13 premium price for the unlawfully, fraudulently, and unfairly marketed, advertised,  
14 packaged, and labeled metformin medication.  
15

16 72. There is no benefit to consumers or competition from deceptively marketing and omitting  
17 material facts concerning the contaminated nature of Defendant's metformin medication.  
18

19 73. Plaintiff and members of the Proposed Class had no reasonable way of knowing that  
20 Defendant's metformin medication they purchased was not as marketed, advertised,  
21 packaged, or labeled. Plaintiff and members of the Proposed Class are not able to test for  
22 the presence of NDMA in their metformin medications. Thus, Plaintiff and members of  
23 the Proposed Class could not have reasonably avoided the injury each of them suffered.  
24

25 74. The gravity of the consequences of Defendant's conduct as described herein outweighs  
26 any justification, motive, or reason therefore, particularly considering the available legal  
27 alternatives which exist in the marketplace. Such conduct by Defendant was and is  
28

1 immoral, unethical, unscrupulous, offends established public policy, and is substantially  
2 injurious to Plaintiff and members of the Proposed Class.

3  
4 75. Defendant's violation has continuing and adverse effects because Defendant's unlawful  
5 conduct is continuing, with no indication that Defendant intends to cease this fraudulent  
6 course of conduct. The public and class members are subject to ongoing harm because  
7 Defendant has not issued a recall for its contaminated metformin medication.

8  
9 76. Plaintiff and the Proposed Class lost money and/or property as a result of Defendant's  
10 violations of California's UCL because: (i) they would not have purchased Defendant's  
11 metformin on the same terms if they knew that the metformin contained harmful levels of  
12 NDMA, and is not generally recognized as safe for human consumption; and (b)  
13 metformin does not have the characteristics, ingredients, uses, or benefits as promised by  
14 Defendant.

15  
16 77. Pursuant to California Business & Professions Code §17203, Plaintiff and the Proposed  
17 Class seek an order of this Court that includes, but is not limited to, requiring Defendant  
18 to: (i) provide restitution to Plaintiff and the members of the Proposed Class; (ii) disgorge  
19 all revenues obtained as a result of violations of the UCL; and (c) pay Plaintiff and the  
20 Proposed Class' attorney's fees and costs.  
21

22  
23 //

24 //

25 //

26 //

27 //

28 //


**PRAYER**

WHEREFORE, Plaintiff prays that the Court enter judgment and orders in their favor and against all Defendants, and Each of Them, as follows:

1. An Order certifying the Class and appointing Plaintiff as the representative of the Proposed Class, and appointment Plaintiff's counsel as lead counsel for the Proposed Class;
2. An Order declaring that the actions of Defendant, as set forth above, violate the law in the respects alleges;
3. For judgment against Defendant for all economic, monetary, actual, consequential compensatory, and treble damages caused by its conduct;
4. For pre-judgment and post-judgment interest;
5. For declaratory judgment and injunctive relief consistent with the foregoing;
6. For reasonable attorneys' fees pursuant to C.C.P. §1021.5;
7. For punitive and exemplary damages;
8. For costs incurred in bringing suit;
9. For such other and further relief as the Court may properly and justly award.

Respectfully Submitted,

**JENSEN & ASSOCIATES**  
*Trial Lawyers*

  
PAUL ROLF JENSEN  
Attorneys for Plaintiffs

Dated: June 29, 2020

**DEMAND FOR JURY TRIAL**


Based on the foregoing, Plaintiff, on behalf of himself, and all others similarly situated, hereby demand a jury trial for all claims so triable.

Dated: June 29, 2020

Respectfully Submitted,

**JENSEN & ASSOCIATES**

*Trial Lawyers*

A handwritten signature in black ink, appearing to read "Paul Rolf Jensen", is written over a horizontal line.

PAUL ROLF JENSEN  
Attorneys for Plaintiffs